United Therapeutics (UTHR) Net Income towards Common Stockholders (2009 - 2026)
United Therapeutics' Net Income towards Common Stockholders came in at $333 million for Q2 2026, up 7.6% from $309.5 million a year earlier and up 21.1% from the prior quarter.
Powered by 
Analysis
United Therapeutics (UTHR) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, United Therapeutics reported Net Income towards Common Stockholders of $1.31 billion, up 5.5% year-over-year; for FY2025, it was $1.33 billion, up 11.7% from FY2024.
- Net Income towards Common Stockholders has increased in each of the last four years, with a five-year compound annual growth rate of 21.0% (FY2020 to FY2025).
- Going back by year, Net Income towards Common Stockholders was $1.2 billion in FY2024 (+21.4%), $984.8 million in FY2023 (+35.4%), $727.3 million in FY2022 (+52.9%) and $475.8 million in FY2021 (-7.6%).
- The five-year range for quarterly Net Income towards Common Stockholders is $112.2 million (Q4 2021) to $364.3 million (Q4 2025).
- Year-over-year, Net Income towards Common Stockholders increased in seven of the last eight quarters, with growth averaging 11.8%.
- The fastest year-over-year change in Net Income towards Common Stockholders over five years came in Q1 2022 (growth of 747.7%), and the weakest in Q2 2022 (a decline of 32.8%).
- Business Quant data shows UTHR's Net Income towards Common Stockholders at $274.9 million (Q1 2026), $364.3 million (Q4 2025) and $338.7 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | United Therapeutics | 23.12 Bn | 12.61 Bn | 683.80 Mn | 333.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 333.00 Mn |
| Mar 31, 2026 | 274.90 Mn |
| Dec 31, 2025 | 364.30 Mn |
| Sep 30, 2025 | 338.70 Mn |
| Jun 30, 2025 | 309.50 Mn |
| Mar 31, 2025 | 322.20 Mn |
| Dec 31, 2024 | 301.30 Mn |
| Sep 30, 2024 | 309.10 Mn |
| Jun 30, 2024 | 278.10 Mn |
| Mar 31, 2024 | 306.60 Mn |
| Dec 31, 2023 | 217.10 Mn |
| Sep 30, 2023 | 267.60 Mn |
| Jun 30, 2023 | 259.20 Mn |
| Mar 31, 2023 | 240.90 Mn |
| Dec 31, 2022 | 132.10 Mn |
| Sep 30, 2022 | 239.30 Mn |
| Jun 30, 2022 | 116.00 Mn |
| Mar 31, 2022 | 239.90 Mn |
| Dec 31, 2021 | 112.20 Mn |
| Sep 30, 2021 | 162.70 Mn |
API Access
United Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=UTHR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "UTHR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=UTHR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();